CommercialPrior AuthMedium impact
Luspatercept-aamt (Reblozyl®)
BCBS Tennessee·TN · Hematology, Oncology·Medical Policy
Effective date
Sep 30, 2026
We identified it
Jul 17, 2026
Summary
BlueCross BlueShield of Tennessee has issued a new medical policy for Luspatercept-aamt (Reblozyl®) effective 9/30/2026, establishing coverage criteria for three indications: beta thalassemia, myelodysplastic syndrome/myeloproliferative neoplasm, and myelofibrosis-associated anemia. Prior authorization is required for all uses, with specific clinical documentation and prescriber specialty requirements. This policy applies to Commercial plans in Tennessee only and includes specific transfusion burden thresholds and hemoglobin level requirements for coverage approval.
Action Required
By September 30, 2026: (1) Update billing system and prior authorization software to recognize Reblozyl (Luspatercept-aamt) as a covered drug requiring prior auth for all three indications (beta thalassemia, MDS/MPN, myelofibrosis). (2) Configure system to require pretreatment/pretransfusion hemoglobin level ≤11 g/dL documentation and RBC transfusion history (≥6 units in 24 weeks for thalassemia; ≥2 units per 8 weeks for MDS/MPN). (3) Add prescriber specialty validation: hematologist/beta thalassemia specialist for thalassemia cases; hematologist or oncologist for MDS/MPN and myelofibrosis cases. (4) Implement exclusion edits for beta thalassemia: deny coverage if member has hemoglobin S/β-thalassemia, alpha-thalassemia, or concurrent mitapivat use. (5) Set authorization duration limits in system: 16 weeks initial (beta thalassemia), 24 weeks initial (MDS/MPN), 12 months initial (myelofibrosis), 12 months for continuation therapy. (6) Coordinate with providers to submit Hemoglobin electrophoresis/HPLC or molecular genetic testing results for thalassemia cases. (7) Update intake forms and prior auth templates to capture required documentation. Billing team and IT must coordinate; failure to implement will result in claim denials and authorization delays.